To ensure the best medical care for newly diagnosed Parkinson's patients, a method of predicting cognitive and motor progress beyond the use of purely clinical parameters would have a major treatment impact. A new study published in the Journal of Parkinson's Disease suggests that a blood test for inflammation and cell aging biomarkers could be a reliable predictor of cognitive decline, including identifying those who have early dementia and in Parkinson's patients will develop early motor progression.
further articles on the same topic
If you would like to be informed about new videos, just send me your email address
[email-subscribers-form id=”2″]
Do you like the Parkinson Journal?
Your rating
[Total: 1 Average: 5]
Share the Parkinson Journal with your friends